IRISH JOURNAL OF
PSYCHOLOGICAL MEDICINE
VOL 20 NO 2 JUNE 2003 ISSN 0790-9667

'Jet Plane, Blue, Red, Yellow, Green, Boxes, Arrows on Grand Parade, Chinese Version'
(detail) by John the Painter (gouache on brown paper, 214 x 511cm)
From an exhibition at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8.

Submissions & correspondence to:
The Editor,
Irish Journal of Psychological Medicine,
25 Adelaide Street,
Dun Laoghaire,
Co Dublin, Ireland.

Telephone: 00-353-1-2803967

Fax: 00-353-1-2807076

Email: psychological@medmedia.ie

Website: www.ijpm.org

Publisher
MedMedia Ltd.
25 Adelaide Street, Dun Laoghaire,
Co Dublin, Ireland.

Printing: W&G Bairds Ltd

Subscriptions
Rates per volume of four issues (Mar, Jun, Sept, Dec) Price Regions:
EU countries: €107, Stg65
Rest of World: €126, $111
Incl. airmail postage internationally.

Subscription enquiries, orders and cheques made payable to:
Turpin Distribution Service Ltd
Blackhorse Road, Letchworth
SG6 1HN, England.
Tel : +44 01462 672555
Fax: + 44 01462 480947
Email: CustServTurpin@turpinltd.com
www.turpin-distribution.com

Circulation
2,200 to 54 countries.
The Journal participates in the World Health Organisation project to improve distribution of scientific materials on mental health. Publication does not imply endorsement.

IRISH JOURNAL OF **PSYCHOLOGICAL MEDICINE**

VOL 20 NO 2 JUNE 2003 ISSN 0790-9667

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from **University Microfilms International**, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the **Adonis** service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in **Ulrich's** International Periodicals Directory (**Bowker** International Serials Database), **EBSCO's** Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

https://doi.org/10.1017/S0790966700007552 Published online by Cambridge University Press



MORE THAN A NAME *by Jerry Ham (Alzheimer's carer)*

once daily

Aricept™

donepezil hydrochloride

Making a difference in Alzheimer's

Pfizer NEUROSCIENCE

Abbreviated Prescribing Information for ARICEPT™ (donepezil) Republic of Ireland

ARICEPT™ (donepezil hydrochloride) Please refer to the SmPC before prescribing ARICEPT 5 mg or ARICEPT 10 mg. **Indication:** Symptomatic treatment of mild to moderately severe Alzheimer's dementia. **Dose and administration:** *Adults/elderly;* 5 mg daily which may be increased to 10 mg once daily after at least one month. No dose adjustment necessary for patients with renal impairment. Dose escalation, according to tolerability, should be performed in patients with mild to moderate hepatic impairment. ***Children;*** Not recommended. **Contra-Indications:** Pregnancy. Hypersensitivity to donepezil, piperidine derivatives or any excipients used in ARICEPT. **Lactation:** Excretion into breast milk unknown. Women on donepezil should not breast feed. **Warnings and Precautions:**Initiation and supervision by a physician with experience of Alzheimer's dementia. A caregiver should be available to monitor compliance. Regular monitoring to ensure continued therapeutic benefit, consider discontinuation when evidence of a therapeutic effect ceases. Exaggeration of succinylcholine-type muscle relaxation. Avoid concurrent use of anticholinesterases, cholinergic agonists, cholinergic antagonists. Possibility of vagotonic effect on the heart which may be particularly important with "sick sinus syndrome", and supraventricular conduction conditions. There have been reports of syncope and seizures - in such patients the possibility of heart block or long sinusal pauses should be considered. Careful monitoring of patients at risk of ulcer disease including those receiving NSAIDs. Cholinomimetics may cause bladder outflow obstruction. Seizures occur in Alzheimer's disease and cholinomimetics have the potential to cause seizures and they may also have the potential to exacerbate or induce extrapyramidal symptoms. Care in patients suffering asthma and obstructive pulmonary disease. As with all Alzheimer's patients, routine evaluation of ability to drive/operate machinery. No data available for patients with severe hepatic impairment. **Drug Interactions:**Experience of use with concomitant medications is limited, consider possibility of as yet unknown interactions. Interaction possible with inhibitors or inducers of Cytochrome P450; use such combinations with care. Possible synergistic activity with succinylcholine-type muscle relaxants, beta-blockers, cholinergic or anticholinergic agents. **Side effects:** Most commonly diarrhoea, muscle cramps, fatigue, nausea, vomiting, and insomnia. Common effects (>1/100, <1/10): common cold, anorexia, hallucinations, agitation, aggressive behaviour, syncope, dizziness, insomnia, diarrhoea, vomiting, nausea, abdominal disturbance, rash, pruritis, muscle cramps, urinary incontinence, headache, fatigue, pain, accident. Uncommon effects (>1/1000, <1/100): seizure, bradycardia, gastrointestinal haemorrhage, gastric & duodenal ulcers, minor increases in serum creatine kinase. Rare (>1/100,000,<1/10,000): extrapyramidal symptoms, sino-atrial block, atrioventricular block, liver dysfunction including hepatitis. **Legal Category:** POM. **Presentation:** Blister packed in strips of 14. ARICEPT 5 mg; white, film coated tablets marked 5 and Aricept, packs of 28. ARICEPT 10 mg; yellow, film coated tablets marked 10 and Aricept, packs of 28. **Marketing authorisation numbers:** ARICEPT 5 mg; PA 822/2/1. ARICEPT 10 mg; PA 822/2/2. **Marketing authorisation holder:** Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. **Further Information from/Marketed by:** Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. **Date of preparation:** : January 2002

Pfizer

1002-04-01

https://doi.org/10.1017/S0790966700007552 Published online by Cambridge University Press